Multicenter Preclinical Validation of BET Inhibition for the Treatment of Pulmonary Arterial Hypertension

What is it about?

Pulmonary arterial hypertension (PAH) is a severe disease of the lung arteries that currently has no cure. We show that inhibition of BRD4, a protein shown before to be involved in the progression of PAH, reverses the disease in different rat models of PAH. Moreover, BRD4 inhibition supported the function of the right ventricle, which is often compromised in patients with PAH.

Featured Image